388: The FDA's refusal to review Moderna's mRNA flu vaccine

What It Covers

The FDA refuses to review Moderna's mRNA flu vaccine application despite prior approval of trial design. Director Vinay Prasad overrules vaccine office staff, demanding high-dose comparator instead of standard-dose vaccine used in the 41,000-person trial that showed 27% greater effectiveness and 49% fewer hospitalizations.

Key Questions Answered

• •Regulatory Precedent Reversal: Moderna received written FDA approval in 2023 for using standard-dose flu vaccine as comparator in their phase three trial, matching the exact methodology used by two currently approved enhanced flu vaccines (Fluzone HD and Flublok) that showed 24% and 30% efficacy improvements respectively, yet Prasad now rejects this approach eighteen months after trial initiation.
• •mRNA Manufacturing Advantage: mRNA flu vaccines allow strain selection as late as June versus February for traditional egg-based vaccines, enabling better matching to circulating viruses. The US has selected different COVID strains than Europe in two of the last four years using this flexibility, demonstrating potential for improved flu vaccine effectiveness through later strain selection and regional customization.
• •Refuse-to-File Rarity: FDA refuses to file only four percent of applications, typically due to missing data or quality defects that make applications nonreviewable. This case marks an unprecedented situation where the agency rejects an application based on trial design it previously approved in writing, with the center director overriding vaccine office staff recommendations to proceed with standard review.
• •Supporting Immunogenicity Data: Moderna conducted a separate phase three study comparing their mRNA vaccine to Fluzone HD in patients 65 and older, showing statistically superior neutralizing antibody titers and seroconversion rates. The FDA specifically requested this data be included in the August 2025 submission, yet still refused to review the complete package containing both efficacy and immunogenicity evidence.
• •Industry Investment Impact: Developing vaccines requires approximately one billion dollars and five years of FDA collaboration for phase three trials. Changing regulatory requirements after trial completion creates unpredictable investment environment where companies cannot rely on written agency guidance, potentially deterring future vaccine innovation beyond just mRNA technology across all therapeutic areas requiring large-scale clinical trials.